155 related articles for article (PubMed ID: 16950396)
1. Quantitative evaluation of each catalytic subsite of cathepsin B for inhibitory activity based on inhibitory activity-binding mode relationship of epoxysuccinyl inhibitors by X-ray crystal structure analyses of complexes.
Watanabe D; Yamamoto A; Tomoo K; Matsumoto K; Murata M; Kitamura K; Ishida T
J Mol Biol; 2006 Oct; 362(5):979-93. PubMed ID: 16950396
[TBL] [Abstract][Full Text] [Related]
2. Crystal structure of an elastase-specific inhibitor elafin complexed with porcine pancreatic elastase determined at 1.9 A resolution.
Tsunemi M; Matsuura Y; Sakakibara S; Katsube Y
Biochemistry; 1996 Sep; 35(36):11570-6. PubMed ID: 8794736
[TBL] [Abstract][Full Text] [Related]
3. The binding mode of an E-64 analog to the active site of cathepsin B.
Feng MH; Chan SL; Xiang Y; Huber CP; Lim C
Protein Eng; 1996 Nov; 9(11):977-86. PubMed ID: 8961350
[TBL] [Abstract][Full Text] [Related]
4. Design of noncovalent trypsin inhibitor based on the X-ray crystal structure of the complex.
Nakamura M; Tomoo K; Ishida T; Taguchi H; Tsuda Y; Okada Y; Okunomiya A; Wanaka K; Okamoto S
Biochem Biophys Res Commun; 1995 Aug; 213(2):583-7. PubMed ID: 7646515
[TBL] [Abstract][Full Text] [Related]
5. Nonpeptidal P2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluation.
Ghosh AK; Kincaid JF; Walters DE; Chen Y; Chaudhuri NC; Thompson WJ; Culberson C; Fitzgerald PM; Lee HY; McKee SP; Munson PM; Duong TT; Darke PL; Zugay JA; Schleif WA; Axel MG; Lin J; Huff JR
J Med Chem; 1996 Aug; 39(17):3278-90. PubMed ID: 8765511
[TBL] [Abstract][Full Text] [Related]
6. The refined 2.15 A X-ray crystal structure of human liver cathepsin B: the structural basis for its specificity.
Musil D; Zucic D; Turk D; Engh RA; Mayr I; Huber R; Popovic T; Turk V; Towatari T; Katunuma N
EMBO J; 1991 Sep; 10(9):2321-30. PubMed ID: 1868826
[TBL] [Abstract][Full Text] [Related]
7. Small molecule interactions with protein-tyrosine phosphatase PTP1B and their use in inhibitor design.
Burke TR; Ye B; Yan X; Wang S; Jia Z; Chen L; Zhang ZY; Barford D
Biochemistry; 1996 Dec; 35(50):15989-96. PubMed ID: 8973169
[TBL] [Abstract][Full Text] [Related]
8. Crystal structure of cathepsin B inhibited with CA030 at 2.0-A resolution: A basis for the design of specific epoxysuccinyl inhibitors.
Turk D; Podobnik M; Popovic T; Katunuma N; Bode W; Huber R; Turk V
Biochemistry; 1995 Apr; 34(14):4791-7. PubMed ID: 7718586
[TBL] [Abstract][Full Text] [Related]
9. Nonpeptidic potent HIV-1 protease inhibitors.
Prasad JV; Lunney EA; Para KS; Tummino PJ; Ferguson D; Hupe D; Domagala JM; Erickson JW
Drug Des Discov; 1996 Apr; 13(3-4):15-28. PubMed ID: 8874041
[TBL] [Abstract][Full Text] [Related]
10. Enkephalin-degrading dipeptidylaminopeptidase: characterization of the active site and selective inhibition.
Chérot P; Devin J; Fournié-Zaluski MC; Roques BP
Mol Pharmacol; 1986 Oct; 30(4):338-44. PubMed ID: 3531805
[TBL] [Abstract][Full Text] [Related]
11. Molecular structure at 1.8 A of mouse liver class pi glutathione S-transferase complexed with S-(p-nitrobenzyl)glutathione and other inhibitors.
García-Sáez I; Párraga A; Phillips MF; Mantle TJ; Coll M
J Mol Biol; 1994 Apr; 237(3):298-314. PubMed ID: 8145243
[TBL] [Abstract][Full Text] [Related]
12. Bovine thrombin complexed with an uncleavable analog of residues 7-19 of fibrinogen A alpha: geometry of the catalytic triad and interactions of the P1', P2', and P3' substrate residues.
Martin PD; Malkowski MG; DiMaio J; Konishi Y; Ni F; Edwards BF
Biochemistry; 1996 Oct; 35(40):13030-9. PubMed ID: 8855938
[TBL] [Abstract][Full Text] [Related]
13. Exploring the binding preferences/specificity in the active site of human cathepsin E.
Rao-Naik C; Guruprasad K; Batley B; Rapundalo S; Hill J; Blundell T; Kay J; Dunn BM
Proteins; 1995 Jun; 22(2):168-81. PubMed ID: 7567964
[TBL] [Abstract][Full Text] [Related]
14. Comparative modeling of substrate binding in the S1' subsite of serine carboxypeptidases from yeast, wheat, and human.
Elsliger MA; Pshezhetsky AV; Vinogradova MV; Svedas VK; Potier M
Biochemistry; 1996 Nov; 35(47):14899-909. PubMed ID: 8942654
[TBL] [Abstract][Full Text] [Related]
15. Structure-based understanding of ligand affinity using human thrombin as a model system.
Nienaber VL; Mersinger LJ; Kettner CA
Biochemistry; 1996 Jul; 35(30):9690-9. PubMed ID: 8703940
[TBL] [Abstract][Full Text] [Related]
16. Inactivation of cysteine proteases.
Govardhan CP; Abeles RH
Arch Biochem Biophys; 1996 Jun; 330(1):110-4. PubMed ID: 8651683
[TBL] [Abstract][Full Text] [Related]
17. Structure-based design of HIV protease inhibitors: 5,6-dihydro-4-hydroxy-2-pyrones as effective, nonpeptidic inhibitors.
Thaisrivongs S; Romero DL; Tommasi RA; Janakiraman MN; Strohbach JW; Turner SR; Biles C; Morge RR; Johnson PD; Aristoff PA; Tomich PK; Lynn JC; Horng MM; Chong KT; Hinshaw RR; Howe WJ; Finzel BC; Watenpaugh KD
J Med Chem; 1996 Nov; 39(23):4630-42. PubMed ID: 8917652
[TBL] [Abstract][Full Text] [Related]
18. Novel peptidyl alpha-keto amide inhibitors of calpains and other cysteine proteases.
Li Z; Ortega-Vilain AC; Patil GS; Chu DL; Foreman JE; Eveleth DD; Powers JC
J Med Chem; 1996 Sep; 39(20):4089-98. PubMed ID: 8831774
[TBL] [Abstract][Full Text] [Related]
19. Clarification of substrate specificity of papain by crystal analyses of complexes with covalent-type inhibitors.
Matsumoto K; Murata M; Sumiya S; Kitamura K; Ishida T
Biochim Biophys Acta; 1994 Oct; 1208(2):268-76. PubMed ID: 7947958
[TBL] [Abstract][Full Text] [Related]
20. From good substrates to good inhibitors: design of inhibitors for serine and thiol proteases.
Baggio R; Shi YQ; Wu YQ; Abeles
Biochemistry; 1996 Mar; 35(11):3351-3. PubMed ID: 8639483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
